News Focus
News Focus
icon url

jav0033

04/02/26 12:43 PM

#516717 RE: tradeherpete #516716

All it matters is CHMP rejected Blarcamesineee TWICE. 
Management is hiding critical information apparently. Missling is a COWARD.
icon url

WilliamMunny

04/02/26 1:06 PM

#516722 RE: tradeherpete #516716

You might go ahead and ask whichever A1 you selected to tell us how much efficacy LEQEMBI (Lecanemab) demonstrated in reducing cognitive decline for women, who represent about two-thirds of all Alzheimer's patients.